Doane Chilcoat
About
Doane Chilcoat is from San Diego Metropolitan Area. Doane is currently Board Member at Mycofeast. Doane also works as Chief Technology Officer at Design Therapeutics, a job Doane has held since Jun 2021. In Doane's previous role as a Chair, Science and Industry Advisory Committee at Genome Canada, Doane worked in until Jun 2022. Prior to joining Genome Canada, Doane was a Chief Technology Officer, State of Iowa and Chair, Iowa Innovation Council at Iowa Economic Development Authority and held the position of Chief Technology Officer, State of Iowa and Chair, Iowa Innovation Council. Prior to that, Doane was a Leader, Applied Science and Technology at Corteva Agriscience, based in Johnston, Iowa from Sep 2017 to May 2021. Doane started working as Director, Applied Technology Systems at DuPont Pioneer in Johnston, Iowa in Jun 2011. From May 2010 to Feb 2011, Doane was President and CEO at Cobax Biopharma, based in Boulder County, Colorado, United States. Prior to that, Doane was a Associate Principal at McKinsey & Company, based in Chicago, Illinois, and LA, California from Jan 1999 to Jan 2010. Doane started working as Senior Director at Replidyne in Boulder County, Colorado in Jan 2006.
Doane Chilcoat's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Doane Chilcoat's current jobs
Developing novel small molecules to address the underlying cause of genetic diseases.
Doane Chilcoat's past jobs
Reported to CTO. Functional responsibility for large segment of Corteva's R&D organization, focused on molecular genetics. As side project led establishment of CLIA-certified Covid testing lab that developed one of first commercial saliva-based tests and went on to develop an ultra-high throughput low-cost endpoint PCR test using the Nexar system
Leader of 450 person R&D group with 6 global locations responsible for transgenic product development and genomics. Built world class competencies in NGS (including novel applications of Illumina, PacBio, and Bionano), plant transformation, genome editing (including discovery and development of a novel Cas system), molecular analysis, and plant phenotyping.
Co-founder of bacteriotherapy company focused on C. difficile
Leader in McKinsey's pharmaceutical practice with therapeutic focus on oncology and functional focus on R&D operations (Fall 1999 to Spring 2006 and Fall 2008 to Spring 2010)
Designed and built specialty anti-infective sales force including physician targeting, training, and operations. Supported BD efforts including early stage in-licensing and partnering of Phase 3 program to big pharma.